1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Code

Showing 1,267 results.

MDS - 838

Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

Rami Komrokji

Poster Presenter: Rami Komrokji

$Thumbnail for A Multicenter, Open-Label, Phase 3, Randomized Trial of Duvelisib vs Investigator's Choice (Gemcitabine or Bendamustine) in Relapsed/Refractory Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype$

TCL - 839

A Multicenter, Open-Label, Phase 3, Randomized Trial of Duvelisib vs Investigator's Choice (Gemcitabine or Bendamustine) in Relapsed/Refractory Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Sheila Waters

Poster Presenter: Sheila Waters

SOHO 2026 Annual Meeting

Posters by Code

Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

A Multicenter, Open-Label, Phase 3, Randomized Trial of Duvelisib vs Investigator's Choice (Gemcitabine or Bendamustine) in Relapsed/Refractory Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

The Role of Blinatumomab in CD19-Positive Precursor B-Cell Acute Lymphoblastic Leukemia Philadelphia-Negative Disease: A 3-Year Update on Progression-Free Survival

Transformation of Multiple Myeloma Survival in the Novel Therapy Era: From a Once Rapidly Fatal Disease to a Chronic Malignancy

All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity

Impact of Structured Mock Runs on Trial Execution: A Comparative Study of Two Cellular Therapy Protocols

THE IMPACT OF FIRST-LINE DARATUMUMAB ON LIGHT-CHAIN AMYLOIDOSIS SURVIVAL: A REAL-WORLD ANALYSIS OF 70 PATIENTS

Treatment-Related Mortality and Predictors in Real-World Patients With Relapsed/Refractory Multiple Myeloma Treated With Teclistamab

In-Hospital Mortality and 30-Day Readmissions in Patients With Myeloproliferative Neoplasm Hospitalized With NSTEMI: A Nationwide Analysis Stratified by Revascularization Strategy